Spermosens

With a structured approach to addressing major fertility markets, Spermosens is making significant progress towards strategic partnerships globally. Interest in Spermosens' unique and patented technology is strong, with promising discussions underway in several key regions. In the US, Spermosens has partnered with ScanMed Partners, a firm specialized in identifying suitable partners for Scandinavian healthcare solutions, and discussions with potential partners are ongoing. In Europe, the company is engaged in discussions with potential partners with a global reach, exploring opportunities to leverage Spermosens' technology. Recently, Spermosens signed a memorandum of understanding with a well-established Japanese company to explore commercialization opportunities in Japan. Formal negotiations are set to begin within the coming weeks. The company is also in close contact with a network of key opinion leaders and business stakeholders in the region to solidify its business development activities. Furthermore, potential partners in South Korea have expressed interest in exploring business opportunities with Spermosens, underscoring the global appeal of its innovative solutions for fertility diagnostics.

Feedback from these discussions indicates that the sperm bank sector could represent a particularly promising market for Spermosens' technology. Leading sperm banks are increasingly looking for competitive advantages and improved selection of high-quality donors. The global sperm bank market was valued at approximately USD 5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of around 4% through 2030 (Grand View Research, 2023). Spermosens' technology offers sperm banks the ability to improve donor selection and increase IVF success rates, ultimately leading to higher birth rates from successful fertility treatments.

Tore Duvold, CEO of Spermosens, comments: "We are encouraged by the strong interest in our JUNO-Checked system from various regions. The feedback from our discussions with sperm banks highlights a growing demand for improved donor selection and higher success rates in fertility treatments. This is an important opportunity for Spermosens, as we continue to work towards bringing our innovative technology to market through strategic partnerships."

Spermosens remains committed to advancing its efforts to identify and secure licensing agreements and partnerships that will allow JUNO-Checked to reach global markets and significantly improve fertility diagnostics and treatments worldwide.

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com